Abstracts less likely to be tested for HBV than for HIV VL in the first six months (21% vs 79%, P <0.0001) and eight times less likely in the last six months of observation (6% vs 49%, P <0.0001). Comparing the first six months to the last six months of observation, the proportion of patients tested for AST (77% and 50% P < 0.0001) and platelets (76% and 57% P < 0.0001) declined.
Background. Co-infection with HIV and hepatitis B virus (HBV) is common, reaching 23% in Uganda, and can accelerate HBV disease progression. Inflammation contributes to the pathogenesis of both viruses. We compared serological biomarkers of inflammation and FIB-4 scores (to predict liver fibrosis) stratified by HIV and HBV status in a Ugandan cohort.
Methods. Subjects with HIV/HBV co-infection were matched up to 2:1 by age and gender with HIV-monoinfected, HBV-monoinfected, and uninfected controls from the Ugandan site of the African Cohort Study (AFRICOS). Demographic and laboratory characteristics, including inflammatory biomarkers, were compared between the groups. FIB-4 scores were stratified as <1. 45, 1.45-3.25, and >3.25 for those unlikely to have advanced fibrosis, indeterminate, and likely to have advanced fibrosis, respectively (resp.), in the HIV/HBV and HIV groups, which had these data available.
Results. Within the Ugandan subset of AFRICOS, 31 HIV/HBV co-infected patients were available and compared with 62 HIV-monoinfected, 7 (all that were available) HBV-monoinfected, and 62 uninfected subjects. Median age was 37 (range 19-67) years and 78% were male. The HBV group, as compared with the HIV/HBV, HIV, and uninfected groups, had higher prevalence of hepatitis C antibody (29%, 6%, 2%, 3%, resp.; P = 0.04), fewer other active infections (0%, 48%, 52%, 26%, resp.; P = 0.002), fewer non-antiretroviral medications (median 0, 1, 2, 0, resp.; P < 0.001), and a smaller proportion on an antimicrobial (0%, 32%, 37%, 18%, resp.; P = 0.03). The HIV/HBV group had generally higher levels of inflammation overall and statistically had significantly higher levels of MMP-12 and lower levels of FGF-23 compared with the other groups (Figure 1) . The HIV/HBV group had a lower proportion of subjects unlikely to have advanced fibrosis by FIB-4 (Figure 2 ; P = 0.046).
Conclusion. Elevated MMP-12 in the HIV/HBV group suggests that elastin degradation may be a mechanism contributing to the accelerated progression of liver disease seen in co-infection. Prior literature demonstrated that FGF-23 is elevated in end-stage liver disease and predicts mortality, but we did not observe higher levels in HIV/HBV co-infection in this cohort with little advanced liver disease. Further studies are needed to characterize the inflammatory milieu and evaluate the impact of time and treatment of HIV/HBV. and Brian Agan, MDpredictive value for vaccine failure. We retrospectively analyzed the relationship of calculated globulin (CG) levels with HBV vaccine response in participants in the U.S.
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Military HIV Natural History Study (NHS).
Methods. NHS is a longitudinal observational cohort of DoD active duty and beneficiaries with HIV infection, enrolling since 1986. Inclusion criteria was: (1) no current or past HBV or hepatitis C infection (2) HBV vaccination after positive HIV date, (3) available post-vaccination follow-up serum HBV surface antibody (HBsAb) test, (4) CD4 cell count, HIV RNA viral load (VL), and protein levels within 90 days prior to the last vaccine dose. Using a standard approach, CG levels were derived by subtracting the albumin level from total protein. Variables were analyzed using univariate and multivariate logistic regression model.
Results. Data from 674 eligible participants were analyzed. Subjects were 87% male, 44% Caucasian, 41% African-American. At time of last vaccine dose, median values were age, 34 yrs; CD4 cells/uL, 515; nadir CD4 cells/ul, 318. 51% were receiving ART and VL was <400 copies/ml in 51%. Overall, HBV vaccine response rate was 54%. Among CG quartiles, HBV vaccine response was 70%, 60%, 40% and 44% from lowest to highest quartile respectively (P < 0.001). In the multivariate analysis, CD4 cell count, VL and CG were independently associated with vaccine response (Table) .
Conclusion. CG levels at time of last dose independently predicted successful HBV vaccine response in HIV-infected persons. These data suggest B-cell dysfunction, characterized by higher CG levels, may be clinically significant regardless of VL and CD4 cell count. Background. Patients coinfected with HIV and HBV are at higher risk of developing chronic HBV infection, cirrhosis and hepatocellular carcinoma. In Mozambique, where the HIV prevalence is among the highest in the world, the epidemiology of HBV and the profile of HBV resistance to 3TC in HIV-infected patients is barely known. Methods. A cross-sectional study was conducted between May and November 2012 at two health centers in Maputo, Mozambique, to consecutively enroll ART-naïve HIV-infected adults (AN-HIV). All participants were tested for hepatitis B surface antigen (HBsAg). CD4 + T cells count and plasma HBV DNA, HBV genotyping and profile of HBV resistance mutations to 3TC were measured in all coinfected patients.
Results. A total of 518 AN-HIV were enrolled. The median age was 33 years old and 66.8% were women. The median CD4 + T cells count was 361 cells/mm 3 and 47 (9.1%) were coinfected with HBV (HBsAg + ). Out of 46 coinfected patients, 24 (55.2%) had HBV DNA ≥ 20 -< 20 000 and 12 (26.1%) had HBV-DNA ≥20 000. APRI > 2.0 was reported in 4.3% of coinfected and FIB4 > 3.25 was reported in 4.4%. ALT and AST were within normal ranges in all HBsAg + patients. Genotype A was identified in 25/27 (92.6%) and genotype E in 2/27 (7.4%) of patients. No patient had 3TC-resistance mutation.
Conclusion. Data from this study showed that HBV infection was prevalent among ART naïve HIV infected adults in Mozambique. The most frequent genotype of HBV was genotype A and no 3TC-resistance was detected. Overall, our data suggests that integration of screening of HBV into HIV care and treatment activities is needed to improve the health conditions of HIV/HBV coinfected patients. Saturday, October 7, 2017: 12:30 PM Background. Historically, eradication of HCV with interferon-based treatments was linked with decreased incidence of diabetes. While viral clearance with direct acting agents (DAAs) may be associated with acute decreases in fasting glucose levels and hemoglobin A1c (HbA1c), there remains a need for larger prospective studies to address the longterm impact of sustained viral response (SVR) achieved with DAAs on glucose metabolism.
Methods. Prospective longitudinal cohort study of 251 subjects with chronic HCV (100% genotype 1a/b, 31% HIV+, 17% diabetes) evaluated pre-and post-DAA therapy with median follow-up of 28 mos. Change in HbA1c, glucose, lipid and transaminase levels were compared based on SVR, HIV, diabetes status and fibrosis stage.
Results. There was no difference in change in HbA1c between subjects who achieved SVR (n = 241) compared with those who did not. Mean change in HbA1c did not differ from zero (−0.022 ± 0.53%) for those with SVR. Further, when subjects were grouped based on HIV, diabetes or fibrosis stage, there were no significant differences in changes in HbA1c or glucose following SVR. Subjects with HIV had smaller reductions in transaminase values (change ALT −33.3 ± 51 IU/L HIV+ vs. −47.8 ± 45 IU/L HIV-, P = 0.0007). Following SVR, total and LDL cholesterol increased (P = 0.0002 and P = 0.0003, respectively) whereas triglyceride levels decreased (P = 0.008). A greater proportion of subjects (7%) started or increased medication therapy for diabetes following SVR compared with the percentage who decreased diabetes therapy (3%). There was a statistically significant positive correlation between change in BMI and change in HbA1c (r=0.17, P = 0.006).
Conclusion. The current study failed to identify sustained benefits in glucose or HbA1c in HCV treated patients, irrespective of HIV, diabetes or fibrosis stage. HIV infection blunted improvements in transaminase levels related to SVR. While HbA1c
